CD274 and neoplasm: The application of PD-L1 is limited by the variations of time, tumor heterogeneity, and differences in detection method thresholds (Velcheti et al., 2014; McLaughlin et al., 2016; Hui et al., 2017; Mok et al., 2019) The use of tumor mutational burden (TMB) is limited due to the complexity and high cost of whole exon sequencing (WES) (Luo et al., 2019), with the biggest obstacle being the complicated threshold standard, which is difficult to determine (Gandara et al., 2018).